Alder Biopharma Reports Data from PoC Clinical Trial of ALD403, Will Be Presented at AANM

Alder Biopharmaceuticals Inc. today announced that Dr. Peter J. Goadsby, M.D., Ph.D., director, NIHR-Wellcome Trust Clinical Research Facility, King's College London and director, Headache Center, Department of Neurology, University of California, San Francisco, will present results from a randomized, double-blind, placebo-controlled proof-of-concept clinical trial of ALD403 for the prevention of frequent episodic migraine at the American Academy of Neurology Meeting, Friday, May 2, in Philadelphia, Pennsylvania. Key points: * ALD403 met the primary endpoint of the study, significantly reducing mean migraine days per month versus placebo during weeks 5-8. * A single infusion of ALD403 resulted in a 100% decrease in migraine days per month for 27-41% of patients depending on month observed. * A single infusion of ALD403 resulted in 16% of patients having no migraines for the full 3 month study period, while 32% of patients had a 75% decrease in their migraine days for the full 3 month study period, statistically significant reductions (p=0.0001 and p=0.0004, respectively). * ALD403 was well tolerated and there were no differences from placebo in terms of adverse events or laboratory safety data. * ALD403 is a genetically engineered monoclonal antibody that targets CGRP for prevention of migraine. Calcitonin gene-related peptide (CGRP) is a small protein involved in the transmission of and heightened sensitivity to pain experienced in migraine. * The migraine prevention proof of concept trial was conducted in 163 patients with frequent episodic migraine who had on average 9 headache days per month. Patients were given a single intravenous dose of 1000mg of ALD403 or placebo and assessed for three months. * Dr. Goadsby's presentation entitled "Randomized, Double-blind, Placebo-controlled Trial of ALD403: An Anti-CGRP Peptide Antibody in the Prevention of Frequent Episodic Migraine" will be part of the clinical trials plenary session presented on Friday, May 2^nd.